PSE- NEUROLOGY AND PSYCHOLOGY

CASE STUDY Open Access

Lyme disease Neurological Implications: III. *neuroborreliosis* and other Diseases Transmitted by the Lyme Tick Vector

Dr. PSE*

Professor, International Institute of Medicine and Science, California, USA.

Received date: October 08, 2023, **Accepted date:** October 13, 2023, **Published date:** October 19, 2023.

***Corresponding Author:** Dr. PSE. Professor, International Institute of Medicine & Science, California, USA.

Abstract

Lyme neuroborrelliosis is a neurological manifestation of Lyme resulting in a disorder of the central nervous system. Its neurologic symptoms include meningo-radiculitis (more common in European patients), cranial nerve abnormalities, altered mental status, and sensory findings. In this Article, I will present and discuss this disorder and its differential diagnosis from other confounding diseases (acute disseminated encephalomyelitis, amyotrophic lateral sclerosis, Alzheimer's disease, Bell's palsy, multiple sclerosis, and viral meningitis). I will further discuss the several other diseases transmitted by the black-legged tick Ixodes scapularis responsible for Lyme, including anaplasmosis, babesiosis, borrelia miyamotoi disease, ehrlichiosis, and Powassan virus disease, which are all important as co-infective and confounding diseases that hamper the correct diagnosis for Lyme.

Abbreviation

AB: AntiBodies; AD: Alzheimer's Disease; ADE: Acute Demyelinating Encephalomyelitis; ALS: Amyotrophic Lateral Sclerosis; AM: Aseptic Meningitis; BBB: Blood-Brain Barrier; BM: Bacterial Meningitis; BMD: Borrelia Miyamotoi Disease; BP: Bell's Palsy; BUN: Blood Urea Nitrogen; CDC&P: (U.S.) Center for Disease Control & Prevention; CLIA: Clinical Laboratory Improvement Amendments; CNS: Central Nervous System; CSF: CerebroSpinal Fluid; ELISA: Enzyme-Linked ImmunoSorbant Assay; EM: Enteroviral Meningitis; EM: Erythema Migrans; FDA: (U.S.) Food & Drug Administration; HGE: Human Granulocytic Ehrlichiosis; HHV: Human Herpes Virus; HSV: Herpes Simplex Virus; IgM: Immunoglobulin M; LCM: Lymphocytic ChorioMeningitis; LD: Lyme Disease; LNB: Lyme Neuroborrelliosis; MDE: Multiphasic Disseminated Encephalomyelitis; MG: Myasthena Gravis; MND: Motor Neuron Disease; MS: Multiple Sclerosis; PCR: Polymerase Chain Reaction; PVD: Powassan virus disease; RBC: Red Blood Cells; RCT: Randomized Clinical Trial; RDE: Recurrent Disseminated Encephalomyelitis; RHS: Ramsay-Hunt Syndrome; VM: Viral Meningitis.

Keywords

Acute disseminated encephalomyelitis; Alzheimer's disease; Amyotrophic lateral sclerosis; Anaplasmosis; Babesiosis; Bell's palsy; Borrelia miyamotoi disease; Ehrlichiosis; Lyme disease; Lyme neuroborrelliosis; Multiple sclerosis; Powassan virus disease; Viral meningitis.

Introduction

I discuss in this Article III those numerous confounding diseases that must be accounted for to arrive at a correct Lyme disease diagnosis. These include Lyme neuroborrelliosis, including its own confounding diseases (acute disseminated encephalomyelitis, Alzheimer's disease, amyotrophic lateral sclerosis, Bell's palsy, multiple sclerosis, and viral meningitis). The discussion will then naturally progress to those other confounding diseases transmitted by *Borrelia burgdorferi*, the Lyme-causing pathogen (anaplasmosis, babesiosis, borrelia miyamotoi disease, *Ehrlichiosis, and* Powassan virus disease).

On Lyme Neuroborrelliosis

Lyme *neuroborrelliosis* (LNB) is a neurological manifestation of Lyme resulting in a disorder of the central nervous system (CNS). It is caused by the systemic infection of spirochetes of the genus Borrelia.

Signs and symptoms

Neuroborreliosis is often preceded by the typical symptoms of Lyme disease (LD) reviewed in Article I in this series, including the *erythema migrans* (EM) rash and flu-like symptoms such as fatigue, fever, headache, muscle and joint pains. Its neurologic symptoms include meningo-radiculitis (more common in European patients), cranial nerve abnormalities, and altered mental status. Sensory findings may also be present. Although rare, a progressive form of encephalomyelitis may also occur.

In children, symptoms of neuroborreliosis that can occur include headache, sleep disturbance, and symptoms associated with increased intracranial pressure (such as papilledema). Less common childhood symptoms can include meningitis, myelitis ataxia, and chorea. Ocular LD has also been reported, as has neuroborreliosis affecting the spinal cord, but neither of these latter two findings are common.

Differential diagnosis

A number of diseases can produce symptoms similar to those of LNB. They are summarily discussed in the accompanying Appendix and include:

• Acute disseminated encephalomyelitis (ADE);

• Alzheimer's disease (AD);

• Amyotrophic lateral sclerosis (ALS) (aka Lou Gehrig disease).

• Bell's palsy (BP);

• Multiple sclerosis (MS); and

• Viral meningitis (VM).

Diagnosis is determined by clinical examination of visible symptoms. In addition, neuroborreliosis can also be diagnosed serologically to confirm clinical examination via western blot, ELISA, and PCR (see Article II for definitions and explanations of these assays).

Treatment

In the U.S., *neuroborreliosis* is typically treated with intravenous antibiotics which cross the blood-brain barrier (BBB) such as amoxicillin, cefuroxime acetyl, doxycycline. Treatment regimens listed in Table 1 below are for localized (or early) LD. These regimens are guidelines only and may need to be adjusted depending on a person’s age, weight, medical history, underlying health conditions, pregnancy status, or allergies.

Age category	Drug	Dosage (orally)	Maximum	Duration (days)
Adults	Amoxicillin	500 mg (3 times a day)	N/A	14-21
	Cefuroxime axetil	500 mg (2 times a day)	N/A	14-21
	Doxycycline	100 mg (2 times a day)	N/A	10-21
Children	Amoxicillin	50 mg/kg per day divided into 3 doses	500 mg/dose	14-21
	Cefuroxime axetil	30 mg/kg per day divided into 2 doses	500 mg/dose	14-21
	Doxycycline	4 mg/kg per day divided into 2 doses	100 mg/dose	10-21

Source: Adapted from CDC&P

Table 1: Treatment regimens for localized Lyme disease

In the U.S., neuroborreliosis is typically treated with intravenous antibiotics which cross the blood-brain barrier (BBB) such as amoxicillin, cefuroxime acetyl, doxycycline. Treatment regimens listed in Table 1 below are for localized (or early) LD. These regimens are guidelines only and may need to be adjusted depending on a person's age, weight, medical history, underlying health conditions, pregnancy status, or allergies.

Medical condition	Alternative treatment
Intolerance of traditional antibiotics (amoxicilin, cefuroxime acetyl, or doxyxycline)	Macrolides (azithromycin, clarithromycin, or erythromycin)
Neurological or cardiac forms of illness	Other antibiotics (ceftriaxone, or penicillin)

Table 2: Regimens for people with antibiotic intolerance or neurological (or cardiac) illnesses

Note that for people intolerant of amoxicillin, cefuroxime axetil, and doxycycline, the macrolides azithromycin, clarithromycin, or erythromycin may be used, although they have a lower efficacy. People treated with macrolides should be closely monitored to ensure that symptoms resolve. Also, people with certain neurological (or cardiac) forms of illness may require intravenous treatment with antibiotics such as ceftriaxone or penicillin (Table 2).

One relatively small randomized clinical trial (RCT) suggested that ceftriaxone was more effective than penicillin in the treatment of LNB. Other small observational studies suggested ceftriaxone is also effective in children. The recommended duration of treatment is 2-4 weeks.

Several European studies have suggested that oral doxycycline is equally as effective as intravenous ceftriaxone in treating *neuroborreliosis*. Doxycycline has not been widely studied as a treatment in the U.S., but antibiotic sensitivities of prevailing European and U.S. isolates of *Borrelia burgdorferi* tend to be identical. However, doxycycline is generally not prescribed to children due to the risk of bone and tooth damage.

There are several discredited or doubtful treatments for neuroborreliosis, including:

• Colloidal silver therapy;

• Hyperbaric oxygen therapy;

• Injections of hydrogen peroxide and mismacine; and

• Malaria therapy.

Other diseases transmitted by the Lyme tick vector

As seen in Article I (Appendix 1, Table 1), the black-legged tick Ixodes scapularis transmits several other pathogens in addition to Borrelia burgdorferi, which is responsible for LD. Table 3 shows these several other diseases: Anaplasmosis, Babesiosis, Borrelia miyamotoi disease, Ehrlichiosis, and Powassan virus disease.

Tick common name	**Vector**	**Bacterium**	**Disease(s) caused**	**Where found in the U.S.?**	**High-risk seasons**
Black-legged	***Ixodes scapularis***	**o *Borrelia burgdorferi*** **o *Borrelia mayonii*** *o Anaplasma phagocytophilum*	***o Lyme disease*** ***o Lyme disease*** (newly discovered form) **o *Anaplasmosis***	East, upper Midwest, and mid-Atlantic	Spring, Summer, Fall (any time when temperatures are above freezing). All tick life stages bite

		o Borrelia miyamotoi o *Ehrlichia chaffensis, Ehrlichia ewingii, Ehrlichia muris eauclairensis* *o Babesia microti* *o* Powassan virus	o A form of relapsing fever **o *Ehrlichiosis*** **o *Babesiosis*** **o Powassan virus disease**		humans, but lymphs and adults are most commonly found on people

Table 3: Diseases transmitted by the black-legged tick Ixodes scapularis

Because of their importance as co-infective and confounding diseases, it would be appropriate to briefly review these other diseases.

Anaplasmosis

Anaplasmosis is a disease caused by the bacterium *Anaplasma phagocytophilum*. This organism was previously known by other names, including *Ehrlichia equi and Ehrlichia phagocytophilum*, and the disease was also previously known as *human granulocytic* ehrlichiosis (HGE). However, a taxonomic change in 2001 recognized that this organism belonged to the genus Anaplasma, resulting in a change in the name of the disease to *anaplasmosis*.

In the U.S., *anaplasmosis* was first recognized as a human disease in the mid-1990s, but did not become nationally notifiable until 1999. Since it became reportable, the estimated total number of anaplasmosis cases reported to the (U.S.) Center for Disease Control & Prevention (CDC&P) has increased steadily from 351 cases in 2000, to 5,762 in 2017. In 2000, its has also increased from 1.4 cases per million persons to 17.9 cases per million persons in 2017. The case fatality rate (that is, the proportion of *anaplasmosis* patients that reportedly died as a result of the infection) has remained low, at less than 1%.

• Seasonality: Although cases of anaplasmosis can occur during any month of the year, the majority of cases reported to the CDC&P have an illness onset during the summer months and a peak in cases typically occurring in June and July. This period is the

season for increased numbers of nymphal black-legged ticks, which is the primary life stage of this tick that bites humans and can transmit the pathogen. A second, smaller peak occurs in October and November and corresponds with the period of adult black-legged tick activity.

- Geographical distribution: Anaplasmosis is most frequently reported from the upper midwestern and northeastern United States. These areas correspond with the known geographic distribution of the black-legged tick (Ixodes scapularis), the primary tick vector of Anaplasma phagocytophilum. In addition to Borrelia burgdorferi, the LD agent, this tick also transmits other human pathogens and co-infections with these organisms have occasionally been reported. The geographical ranges of anaplasmosis appear to be increasing, which is consistent with the black-legged tick's expanding ranges that have been documented along the Hudson River Valley, Michigan, and Virginia. Eight states (Maine, Massachusetts, Minnesota, New Hampshire, New York, Rhode Island, Vermont, and Wisconsin,) account for 90% of all reported cases of anaplasmosis. Additionally and occasionally, anaplasmosis cases are reported in other parts of the U.S., including southeastern and south-central States where the organism has not been commonly found. Some of these cases might be due to patient travel to States with higher levels of disease, or misdiagnosis of anaplasmosis in patients actually infected with another closely related tick-borne disease (ehrlichiosis).
- People at risk: The frequency of reported cases of anaplasmosis is highest among:
- Males and people over 40 years of age;
- People with weakened immune systems (such as those occurring due to cancer treatments, advanced HIV infection, prior organ transplants, or some medications); and People who live near or spend time in known tick habitats.

Babesiosis

Babesiosis is caused by parasites that infect red blood cells (RBC). Most U.S. cases are caused by *Borrelia microti* (and other *babesia* species), which is transmitted by *Ixodes scapularis* ticks, primarily in the Northeast and Upper Midwest. Babesia parasites also can be transmitted via transfusion, anywhere, at any time of the year. The incubation period is 1–9 weeks or more.

Babesia infection can range from asymptomatic to life threatening. Risk factors for severe *babesiosis* include

asplenia, advanced age, and impaired immune function. Severe cases can be associated with marked thrombocytopenia, disseminated intravascular coagulation, hemodynamic instability, acute respiratory distress, renal failure, hepatic compromise, altered mental status, and death.

Geographical distribution; Babesiosis is most frequently reported from the northeastern and Upper Midwestern United States in areas where Borrelia microti is endemic. Sporadic cases of infection caused by novel babesia agents have been detected in other U.S. regions, including the West Coast. In addition, transfusion-associated cases of babesiosis can occur anywhere in the country.

Signs and symptoms: They include: arthralgia, chill, fatigue, fever, gastrointestinal symptoms (anorexia, nausea); headache, malaise, myalgia, sweats, dark urine. Less common symptoms include: conjunctival infection, cough, depression, emotional lability, other gastrointestinal symptoms (abdominal pain, vomiting), photophobia, and sore throat. Mild symptoms may occur in some patients and include: mild hepatomegaly, mild splenomegaly, or jaundice. Not all infected persons are symptomatic or febrile. The clinical manifestations, if any, usually develop within several weeks after exposure, but may develop or recur months later (for example, in the context of surgical splenectomy).

Diagnosis: In addition to signs and symptoms, the diagnosis is based on general laboratory findings including: decreased hematocrit due to hemolytic anemia, thrombocytopenia; elevated serum creatinine and blood urea nitrogen (BUN) values, and mildly elevated hepatic transaminase values. The laboratory diagnosis includes: identification of intra-erythrocytic babesia parasites by light-microscopic examination of a peripheral blood smear; or positive PCR analysis for Babesia microti; or isolation of babesia parasites from a whole blood specimen by animal inoculation (in a reference laboratory). Note that sometimes it can be difficult to distinguish between babesia and malaria parasites and even between parasites and artifacts (such as stain or platelet debris).

Treatment: In March 2018, the (U.S.) Food & Drug Administration (FDA) approved the first Borrelia microti blood donor screening tests. Congenital transmission has also been reported. Treatment decisions and regimens should consider the patient's age, clinical status, immune-competence, splenic function, co-morbidities, pregnancy status, other medications, and allergies. Expert consultation is recommended for persons who have or are at risk for severe or relapsing infection or who are at either extreme of age. For ill patients, babesiosis usually is treated for at least 7–10 days with a combination of

two medications, typically either (atovaquone + azithromycin) or (clindamycin + quinine: the standard of care for severely ill patients).

Borrelia miyamotoi disease (BMD)

Disseminated by the agent Borrelia myamotoi, and sometimes called hard tick relapsing fever, BMD has been reported as the cause of human infection in the Upper Midwest, the Northeast, and the mid-Atlantic States, in places where LD occurs. However, unlike LD, which is most common in June and July, Borrelia miyamotoi infection occurs most commonly in July and August and may be spread by larval black-legged ticks. The incubation period ranges from days to weeks, but specific ranges are unknown.

Signs and symptoms: They include: abdominal pain, anorexia (uncommon), arthralgia, chills, confusion, diarrhea, dizziness, dyspnea (uncommon), fatigue, fever, headache (severe), myalgia, nausea, rash (uncommon), and vertigo (uncommon).

- Diagnosis: Based on general laboratory findings (elevated hepatic transaminase values, leukopenia, and thrombocytopenia), the laboratory diagnosis relies on PCR tests that detect DNA from the organism; or antibody-based tests. The tests are available from a limited number of CLIA (Clinical Laboratory Improvement Amendments)-approved reference laboratories. Recent studies indicate that the C6 peptide ELISA test (a first-tier test for LD) may be positive in patients infected with Borrelia miyamotoi.

Treatment: To date, there are no comprehensive studies to evaluate treatment regimens but, in published case series, patients were successfully treated with antibiotics and dosages used for LD.

Ehrlichiosis

Ehrlichiosis is the general name used to describe diseases caused by the bacteria *Ehrlichia chaffensis*, *Ehrlichia ewingii*, or *Ehrlichia muris eauclairensis* in the U.S. The majority of reported cases are due to infection by *Ehrlichia chaffensis*.

- **Transmission:** The majority of Ehrlichiosis cases reported to CDC&P have an illness onset during the summer months with a peak in cases typically occurring in June and July. The disease is transmitted in two major ways by:

  - Tick bites: Most people get Ehrlichiosis from the bite of an infected tick, Ehrlichia chaffensis and Ehrlichia ewingii are transmitted by the lone star tick Amblyomma americanum, found primarily in the south-central and eastern U.S. Ehrlichia muris

eauclairensis is spread by the black-legged tick Ixodes scapularis, which is widely distributed in the eastern U.S. although cases have only been reported in transmission but it does not eliminate it.

◦ Organ transplantation: Two instances of Ehrlichia chaffensis transmission through renal transplant from a common donor have been reported. Patients who develop Ehrlichiosis within a month of receiving a blood transfusion or solid organ transplant should be reported to State health officials for prompt investigation.

• Epidemiology: The geographic range of Ehrlichiosis cases depends highly on the species of ehrlichia-causing illness: Ehrlichia chaffensis and Ehrlichia ewingii infections occur primarily in south-central, southeastern, and mid-Atlantic states. Ehrlichiosis muris eauclairensis infections have only been reported from Wisconsin and Minnesota and travelers to those States.

Powassan virus disease (PVD)

Powassan virus infections have been recognized in the U.S., Canada, and Russia. In the U.S., cases have been reported primarily from Northeastern States and the Great Lakes region. The causing agent is the Powassan virus with an incubation period of 1–4 weeks.

• Signs and Symptoms: They include: fever, headache, vomiting, and generalized weakness. The illness usually progresses to meningo encephalitis, which may include: Aphasia, cranial nerve palsies, meningeal signs, altered mental status, movement disorders, paresis, or seizures.

• Diagnosis: In addition to the signs and symptoms jut listed, the diagnosis is based on laboratory findings including: Cerebrospinal fluid (CSF) findings (lymphocytic pleocytosis), normal or mildly elevated protein, and normal glucose. The laboratory diagnosis includes primarily testing (available at CDC&P, selected State Health Departments, and limited commercial testing) and measurement of virus-specific IgM antibodies (AB) in serum or CSF.

• Treatment: No specific antiviral treatment for PWD is available. Patients with suspected PWD should receive supportive care as appropriate.

Summary and conclusions

• Lyme neuroborrelliosis is a neurological manifestation of Lyme resulting in a disorder of the central nervous system that is caused by a systemic infection of spirochetes of the genus Borrelia.

• Neuroborreliosis is often preceded by the

typical symptoms of Lyme disease, including neurologic symptoms (meningo-radiculitis, cranial nerve abnormalities, altered mental status, and sensory findings) that may also be present. Rarely, a progressive form of encephalomyelitis may also occur.

• The diagnosis of neuroborreliosis is determined differentially by clinical examination of visible symptoms and serologically. Confounding other diseases include: acute disseminated encephalomyelitis; Alzheimer's disease; amyotrophic lateral sclerosis; Bell's palsy; multiple sclerosis; and viral meningitis.

• Neuroborreliosis is typically treated with intravenous antibiotics which cross the blood-brain barrier such as penicillin, ceftriaxone, or cefotaxime. There are several discredited or doubtful treatments for neuroborreliosis including: colloidal silver, hyperbaric oxygen therapy; injections of hydrogen peroxide and mismacine, and malaria therapy.

• In addition to Borrelia burgdorferi, which is responsible for Lyme disease, the black-legged tick Ixodes scapularis transmits several other pathogens including anaplasmosis, babesiosis, borrelia miyamotoi disease, ehrlichiosis, and Powassan virus disease. They are important as co-infective and confounding diseases for Lyme.

• Anaplasmosis is a disease caused by the bacterium Anaplasma phagocytophilum. The estimated total number of anaplasmosis cases reported to CDC&P has increased steadily. It is most frequently reported from the upper midwestern and northeastern U.S.

• Babesiosis is caused by parasites that infect red blood cells. Most U.S. cases are caused by Borrelia microti (and other babesia species), which is transmitted by Ixodes scapularis ticks, primarily in the Northeast and Upper Midwest. The parasites can be transmitted via transfusion, anywhere, at any time of the year. Babesia infection can range from asymptomatic to life threatening. Sometimes it can be difficult to distinguish between babesia and malaria parasites.

• Disseminated by the agent Borrelia myamotoi, and sometimes called hard tick relapsing fever,

borreliosis has been reported as the cause of human infection in the Upper Midwest, the Northeast, and the mid-Atlantic States, in places where Lyme disease occurs. To date, there are no comprehensive studies to evaluate treatment regimens, but patients were successfully treated with antibiotics at dosages used for Lyme disease.

• Ehrlichiosis is caused by the bacteria Ehrlichia chaffensis, Ehrlichia ewingii, or Ehrlichia muris eauclairensis in the U.S. The majority of reported cases are due to infection by Ehrlichia chaffensis. The illness onset is during the summer months with a peak in cases typically occurring in June Signs and symptoms include: fever, headache, vomiting, and generalized weakness. The illness usually progresses to meningo-encephalitis, which may include aphasia, cranial nerve palsies, meningeal signs, altered mental status, movement disorders, paresis, or seizures. No specific antiviral treatment is available.

Appendix
Differential diagnosis

Alzheimer's disease (AD)

According to current knowledge, AD is an age-related (not age-caused), progressive, (purportedly) irreversible chronic neurological disorder in which brain cells die slowly destroying memory and thinking skills, eventually even the ability to carry out the simplest tasks. In most people with AD, symptoms first appear after age 60.

The memory loss and the associated cognitive decline had developed for a period of years or decades. When it appears in persons aged in their 30s and mid-60s, it is

and July, primarily in south-central, southeastern, and mid-Atlantic states. The disease is transmitted by tick bites or blood transfusion or/and organ transplant.

• Powassan virus infections have been recognized in the United States, Canada, and Russia.

called early-onset AD but the more prevalent form occurs in the mid-60s and older and is called late-onset AD. In the absence of disease, the human brain often can function well into the 10th decade of life.

In healthy people, all sensations, movements, thoughts, memories, and feelings are the result of signals that pass through billions of nerve cells (or neurons) in the brain. Neurons constantly communicate with each other through electrical charges that travel down axons, causing the release of chemicals across tiny gaps to neighboring neurons.

Other cells in the brain, such as astrocytes and microglia (the brain's “cleaning maids”) clear away debris and help keep neurons healthy. In a person with AD, toxic changes in the brain destroy this healthy balance over years, even decades, Researchers believe that this process involves two proteins called “amyloid-beta” and “tau”, which somehow become toxic to the brain.

It appears that abnormal tau accumulates, eventually forming tangles inside neurons. Also, amyloid-beta clumps into plaques, which slowly build up between neurons. As the level of amyloid reaches a tipping point, there is a rapid spread of tau throughout the brain, pointing to interactions between these two types of proteins. Such interactions have been found to be important and are currently being studied.

But, tau and amyloid-beta proteins may not be the only factors involved in AD. Other changes that affect the brain may also play a role over time. Thus, the vascular system may fail to deliver sufficient blood and nutrients to the brain; the brain may lack the glucose needed to power its activity; chronic inflammation sets in as microglial cells fail to clear away debris; and astrocytes react to distressed microglia.

Eventually, neurons lose their ability to communicate and, as they die, the brain shrinks. This decay process begins in the hippocampus, that part of the brain that is important to learning and memory (see Figure 1).

People may begin to experience memory loss, impaired decision-making, and language problems. As more neurons die throughout the brain, a person with AD gradually loses the ability to think, remember, make decisions, and function independently.

It is readily seen in Figure 1 that the brain structure and convolutions are distorted with extreme shrinkage of the cerebral cortex and the hippocampus and severely enlarged ventricles. The extent of brain shrinkage may be used as a rough gauge for assessing the severity of the disease.



Figure 1: Contrasting a healthy brain with a severe Alzheimer-diseased brain

It is readily seen in Figure 1 that the brain structure and convolutions are distorted with extreme shrinkage of the cerebral cortex and the hippocampus and severely enlarged ventricles. The extent of brain shrinkage may be used as a rough gauge for assessing the severity of the disease.

Achieving a deeper understanding of the molecular and cellular mechanisms—and how they may interact—is vital to the development of effective therapies. Much progress has been made in identifying various underlying factors. Additionally, advances in brain imaging allow us to see the course of plaques and tangles in the living brain.

Blood and fluid biomarkers are further providing insights about when the disease starts and how it progresses. More is also known about the genetic underpinnings of the disease and how they can affect particular biological pathways.

These advances enable the development and testing of promising new therapies, including: drugs that reduce or clear the increase of tau and amyloid proteins in the brain; therapies that target the vascular system, glucose metabolism, and inflammation; lifestyle interventions, like exercise and diet; and behavioral approaches like social engagement and integration that may enhance brain health. Research is moving quickly, ever closer to the day when we can delay or even prevent the devastation of AD and dementia.

(For those readers interested in knowing more about AD and its relationship to LD, I refer them to my book on the subject.)

Acute disseminated encephalomyelitis (ADE)

ADE is a rare autoimmune disease marked by a sudden, widespread attack of inflammation in the brain and spinal cord.

As well as causing the brain and spinal cord to become inflamed, ADE also attacks the nerves of the CNS and damages their myelin insulation, which, as a result, destroys the white matter. It is often triggered by a viral infection or, perhaps exceedingly rarely, specific non-routine vaccinations.



Reference: Rodríguez-Porcel F, Hornik A, Rosenblum J and Biller EBpeni.nlm.nih.gov/detailedresult.php?img=PMC4274983_fneur-05-00270-g002&query=acute+disseminated+encephalomyelitis&lic=by&req=4&npos=17

Figure 2: Fulminating ADE showing many lesions

ADE's symptoms resemble the symptoms of multiple sclerosis (MS, see below), so the disease itself is sorted into the classification of MS borderline diseases. However, it has several features that distinguish it from MS in that it occurs usually in children and is marked with rapid fever, although adolescents and adults can get the disease too. ADE consists of a single flare-up whereas MS is marked with several flare-ups (or relapses), over a long period of time. Relapses following ADE are reported in up to a quarter of patients, but the majority of these "multiphasic" presentations following ADE likely represent MS. ADE is also distinguished by a loss of consciousness, coma, and death, which is very rare in MS, except in severe cases.

ADE affects about 8 per 1,000,000 people per year. Although it occurs at all ages, most reported cases are in children and adolescents with average age around 5-8 years old. The disease affects males and females almost equally. It shows seasonal variation with higher incidence in winter and spring months, which may coincide with higher viral infections during these months. The mortality rate may be as high as 5%; however, full recovery is seen in 50%-75% of cases with increase in survival rates up to 70%-90%, including minor residual disability as well. The average time to recover from ADE flare-ups is 1-6 months.

ADE produces multiple inflammatory lesions in the

brain and spinal cord, particularly in the white matter. Usually these are found in the subcortical and central white matter and cortical gray-white junction of both cerebral hemispheres, brainstem, and spinal cord, but periventricular white matter and gray matter of the cortex, thalamus, and basal ganglia may also be involved (Figure 2). When a person has more than one demyelinating episode of ADE, the disease is then called recurrent disseminated encephalomyelitis (RDE) or multiphasic disseminated encephalomyelitis (MDE).

Viral meningitis VM

VM, also known as aseptic meningitis (AM), is a type of meningitis due to a viral infection. It results in inflammation of the meninges (the membranes covering the brain and spinal cord). Symptoms commonly include headache, fever, sensitivity to light, and neck stiffness (Figure 3).

Viruses are the most common cause with most cases caused by enteroviruses (common stomach viruses). However, other viruses can also cause VM such as, for instance, the West Nile, mumps, measles, herpes simplex types (HSV) I and II, varicella, and lymphocytic choriomeningitis (LCM) viruses.

Based on clinical symptoms, VM cannot be reliably differentiated from bacterial meningitis (BM), although VM typically follows a more benign clinical course. VM has no evidence of bacteria present in the CSF.

Therefore, lumbar puncture with CSF analysis is often needed to identify the disease. In most cases, there is no specific treatment, with efforts generally aimed at relieving symptoms (headache, fever or nausea). A few viral causes, such as HSV, have specific treatments.

In the U.S., VM is the cause of more than half of all cases of meningitis. With the prevalence of BM in decline, the viral disease is garnering more and more attention.

The estimated incidence has a considerable range, from 0.26 to 17 cases per 100,000 people. For enteroviral meningitis (EM), the most common cause of VM, there are up to 75,000 cases annually in the U.S. alone. While the disease can occur in both children and adults, it is more common in children.

Multiple sclerosis (MS)

MS is the most common immune-mediated disorder affecting the central nervous system. It was first described in 1868 by the French neurologist Jean-

Marie Charcot.

The name refers to the numerous glial scars (or sclerae – essentially plaques or lesions) that develop on the white matter of the brain and spinal cord. Figure 4 is a photomicrograph of a demyelinating MS-lesion obtained by immunohistochemical staining for CD68 (original magnification 10x. Marvin 101). It highlights numerous macrophages (in brown color).

In 2015, about 2.3 million people were affected globally, with rates varying widely in different regions and among different populations. In that year, about 18,900 people died, up from 12,000 in 1990. The disease usually begins between the ages of 20 and 50 and is twice as common in women as in men.

MS is a demyelinating disease in which the insulating covers of the nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to transmit signals, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems.

Specific symptoms can include double vision, blindness in one eye, muscle weakness, and trouble with sensation or coordination.

MS takes several forms, with new symptoms either occurring in isolated attacks (relapsing forms) or building up over time (progressive forms). Between attacks, symptoms may disappear completely; however, permanent neurological problems often remain, especially with the advancement of the disease.



Reference: SVG by Mysid, original by SEER Development Team

Figure 3: Depicting the meninges of the central nervous system

While the cause is unclear, the underlying mechanism is thought to be either destruction of the immune system or failure of the myelin-producing cells. Proposed causes for this include genetics and environmental factors such as being triggered by a viral infection. MS is usually diagnosed based on the presenting signs and symptoms and the results of supporting medical tests. There is no known cure for MS. Treatments attempt to improve function after an attack and prevent new attacks.

While modestly effective, medications used can have side effects and be poorly tolerated. Physical therapy can help with people's ability to function. Many people pursue alternative treatments. despite a lack of evidence of benefit. The long-term outcome is difficult to predict, with good outcomes more often seen in women, particularly those who develop the disease early in life, those with a relapsing course, and those who initially experienced few attacks. Life expectancy is on average 5 to 10 years lower than that of the unaffected population. A number of new treatments and diagnostic methods are under development.

(For those readers interested in knowing more about MS and its relationship to LD, I refer them to my book on the subject.)



Figure 4: Photomicrograph of a demyelinating multiple sclerosis lesion

Bell's palsy (BP)

BP is a type of facial paralysis that results in an inability to control the facial muscles on the affected side (Figure 5). It is named after Scottish surgeon Charles Bell (1774–1842), who first described the connection of the facial nerve to the condition. BP is the most common cause of one-sided facial nerve paralysis (70%). It occurs in 1%-4% per 10,000 people per year. About 1.5% of people are affected at some point in their life. It most commonly occurs in people between ages 15 and 60. Males and females are affected equally. Symptoms can vary from mild to severe. They may include muscle twitching, weakness, or total loss of the ability to move one or rarely both sides of the face. Other symptoms include drooping of the eyelid, a change in taste, pain around the ear, and increased sensitivity to sound. Typically symptoms come on over 48 hours.

The cause of BP is unknown. Risk factors include diabetes, a recent respiratory tract infection, and pregnancy. It results from a dysfunction of cranial nerve VII (the facial nerve). Many believe that this is due to a viral infection that results in swelling. Diagnosis is based on a person's appearance and ruling out other possible causes. Other conditions that can cause facial weakness include brain tumor, stroke, Ramsay-Hunt syndrome (RHS), myasthena gravis (MG), and LD. The condition normally gets better by itself with most patients achieving normal or near-normal function. Corticosteroids have been found to improve outcomes, while antiviral medications may be of a small additional benefit. The eye should be protected from drying-up with the use of eye drops or an eyepatch. Surgery is generally not recommended. Often signs of improvement begin within 14 days, with complete recovery within six months. A few may not recover completely or have a recurrence of symptoms.



Source: James Wellman, MD

Figure 5: Bell's palsy

Amyotrophic lateral sclerosis (ALS)

ALS, also known as motor neuron disease (MND) or Lou Gehrig's disease, is a disease that causes the death of neurons controlling voluntary muscles. MND is also the name for a group of conditions of which ALS is the most common. Descriptions of the disease date back to wn in the U.S. in the 20th century when, in 1939, it affected baseball player Lou Gehrig, and later worldwide following the 1963 diagnosis of cosmologist Stephen Hawking. The first ALS gene was at least 1824 by Charles Bell (of the famed Bell's palsy). In 1869, the connection between the symptoms and the underlying neurological problems was first described by Jean-Marie Charcot who, in 1874, began using the term amyotrophic lateral sclerosis. It became well-kno

discovered in 1993 while the first animal model was developed in 1994. In 2014, videos of the Ice Bucket Challenge went viral on the Internet and increased public awareness of the condition..



Source: Frank Gaillard
(http://radiopaedia.org/uploads/radio/0001/2754/ALS_Coronal.jpg)

Figure 6: Amyotrophic lateral sclerosis

ALS is characterized by stiff muscles, muscle twitching, and gradually worsening weakness due to muscles decreasing in size. It may begin with weakness in the arms or legs, or with difficulty speaking or swallowing. About half of the people affected develop at least mild difficulties with thinking and behavior and most people experience pain. Most patients eventually lose the ability to walk, use their hands, speak, swallow, and breathe (Figure 6)

The cause is not known in 90%-95% of cases, but is believed to involve both genetic and environmental factors. The remaining 5%–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.

No cure for ALS is known. The goal of treatment is to improve symptoms. A medication called Riluzole may extend life by about 2-3 months. Non-invasive ventilation may result in both improved quality and length of life. Mechanical ventilation can prolong survival but does not stop disease progression. A feeding tube may help. The disease can affect people of any age, but usually starts around the age of 60 and, in inherited cases, around the age of 50. The average survival from onset to death is 2-4 years, although this can vary. About 10% survive longer than 10 years. Most die from respiratory failure.

In Europe, the disease affects about 2-3 people per 100,000 per year. Rates in much of the world are unclear. In the U.S., it is more common in white people than black people.

References

1. Asch ES, Bujak DI, Weiss M, et al. (1994). “Lyme disease: an infectious and post-infectious syndrome”. J Rheumatol 21(3):454-61.
2. Aucott J, Morrison C, Munoz B, et al. (2009). “Diagnostic challenges of early Lyme disease: lessons from a community case series”. BMC Infect Dis 9:79.
3. Barbour AG and Restrepo BI (2000). “Antigenic variation in vector-borne pathogens”. Emerg Infect Dis 6(5):449-57.

4. Coyle PK and Schutzer SE. (1991). “Neurologic presentations in Lyme disease”. Hosp Pract 26 (11):55-66.discussion 66, 69-70 [Taylor & Francis Online].
5. Donta ST (2012). “Issues in the diagnosis and treatment of Lyme disease. Open Neurol J 6:140-5.
6. Duray PH (1989). “Clinical pathologic correlations of Lyme disease”. Rev Infect Dis 11(Suppl 6):S1487-93.
7. Eikeland R, Mygland A, Herlofson K, and Ljostad U. (2011). “European neuroborreliosis: quality of life 30 months after treatment”. Acta Neurol Scand 124(5):349-54.
8. Fallon BA, Levin ES, Schweitzer PJ, Hardesty D (2010). “Inflammation and central nervous system Lyme disease”. Neurobiol Dis 37(3):534-41.
9. Fymat AL (2017b). “Neurological disorders and the blood-brain barrier: 2. Parkinson's disease and other movement disorders”, Journal of Current Opinions in Neurological Science 2(1)362-83.
10. Fymat AL (2018a). “Blood-brain barrier permeability and neurological diseases”, Journal of Current Opinions in Neurological Science (Editorial).2(2):411-4.
11. Fymat AL (2018b). “Alzheimer's disease: a review”, Journal of Current Opinions in Neurological Science 2(2);415-36,
12. Fymat AL (2018c). “Regulating the brain's autoimmune system: the end of all neurological disorders?” Journal of Current Opinions in Neurological Science 2(3):475-9.
13. Fymat AL (2018d). “Alzheimer's disease: prevention, delay, minimization and reversal”, Journal of Clinical Research in Neurology 1(1):1-16.
14. Fymat AL (2018e). “Harnessing the immune system to treat cancers and neurodegenerative diseases”, Journal of Clinical Research in Neurology 1(1):1-14.
15. Fymat AL (2018f). “Is Alzheimer's an autoimmune disease gone rogue””, Journal of Clinical Research in Neurology 2(1):1-4.
16. Fymat AL (2018g). “Dementia treatment: where do we stand?”, Journal of Current Opinions in Neurological Science 3(1):1-3.
17. Fymat AL (2018h). “On dementia and other cognitive disorders”, Journal of Clinical Research in Neurology 1(2):1-14.
18. Fymat AL (2018i). “Is Alzheimer's a runaway autoimmune Disease? and how to cure it?”, Newsletter European Union Academy of Sciences Annual Report (2018).
19. Fymat AL (2019a). “Is Alzheimer's a runaway autoimmune disease? and how to cure it?” Proceedings of the European Union Academy of Sciences, Newsletter, pages 379-83.

20. Fymat AL (2019b). "Dementia: a review", Journal of Clinical Psychiatry and Neuroscience 1(3):27-34.
21. Fymat AL (2019c). "The pathogenic brain", Journal of Current Opinions in Neurological Science 3(2);669-71.
22. Fymat AL (2019d). "On the pathogenic hypothesis of neurodegenerative diseases", Journal of Clinical Research in Neurology 2(1):1-7.
23. Fymat AL (2019e). "Dementia with Lewy bodies: a review", Journal of Current Opinions in Neurological Science 4(1);15-32.
24. Fymat AL (2019f). "Our two interacting brains: etiologic modulations of neurodegenerative and gastroenteric diseases", Journal of Current Opinions in Neurological Science 4(2):50-4.
25. Fymat AL (2019g). "What do we know about Lewy body dementias?" Journal of Psychiatry and Psychotherapy (Editorial) 2(1)-013:1-4. doi:10.31579/JPP.2019/018.
26. Fymat AL (2019h). "Viruses in the brain...? any connections to Parkinson's and other neurodegenerative diseases?" Proceedings of the European Union Academy of Sciences, 2019 Newsletter.
27. Fymat AL (2019i). "Alzhei … Who? demystifying the disease and what you can do about it", Tellwell Talent Publishers, pp 235, 2019. ISBN: 978-0-2288-2420-6 (Hardcover); 978-0-2288-2419-0 (Paperback).
28. Fymat AL (2020a). "Recent research developments in Parkinson's disease", Current Opinions in Neurological Science 5(1):12-30.
29. Fymat AL (2020b). "The role of radiological imaging in neurodegenerative disorders", Journal of Radiology and Imaging Science 1(1):1-14.
30. Hayes E. (2003). "Lyme disease". Clin Evid (10):887-99.
31. Institute of Medicine, (US) Committee on Lyme Disease and Other Tick-Borne Diseases (2011): "The state of the science". In: "Critical needs and gaps in understanding prevention, amelioration, and resolution of Lyme and other tick-borne diseases: the short-term and long-term outcomes: workshop report". National Academies Press; Washington, DC, USA.
32. Krause PJ, Telford SR 3rd, Spielman A, et al. (1996). "Concurrent Lyme disease and babesiosis: evidence for increased severity and duration of illness". JAMA 275(21):1657-60.
33. Lawrence C, Lipton RB, Lowy FD, and Coyle PK (2012). "Seronegative chronic relapsing neuroborreliosis". Eur Neurol 35(2):113-17.
34. Logigian EL, Kaplan RF, and Steere AC. (1990). "Chronic neurologic manifestations of Lyme disease". N Engl J Med 323(21):1438-44.
35. Pollina DA, Sliwinski M, Squires NK, and Krupp

LB (1999). "Cognitive processing speed in Lyme disease". Neuropsychiatry Neuropsychol Behav Neurol 12(1):72-8.

36. Tang S, Calkins H, and Petri M. (2004). "Neurally mediated hypotension in systemic lupus erythematosus patients with fibromyalgia". Rheumatology 43(5):609-14.
37. Thaisetthawatkul P and Logigian EL (2002). "Peripheral nervous system manifestations of Lyme borreliosis". J Clin Neuromuscul Dis 3(4):165-71.
38. Vazquez M, Sparrow SS, andShapiro ED. (2003). "Long-term neuropsychologic and health outcomes of children with facial nerve palsy attributable to Lyme disease". Pediatrics 112(2): e93-7.